Home/Pipeline/Lerociclib (Lerocliclib)

Lerociclib (Lerocliclib)

Breast Cancer

Phase 3Completed Phase 3, awaiting FDA approval

Key Facts

Indication

Breast Cancer

Phase

Phase 3

Status

Completed Phase 3, awaiting FDA approval

Company

Chemogenics BioPharma

About Chemogenics BioPharma

ChemoGenics BioPharma operates as a preclinical-stage contract research organization (CRO) and drug discovery partner, offering a full suite of services from custom synthesis and medicinal chemistry to in vitro ADME and in vivo PK/PD studies. The company's core strength lies in its team of PhD scientists with over 10+ years of industry experience, enabling them to deliver intellectual property and support clients from target identification to clinical candidate selection. While primarily a service provider, the company's leadership has a proven track record in drug discovery, having invented the commercially marketed CDK4/6 inhibitor Trilaciclib and advanced Lerociclib to Phase 3 trials. Their strategic focus is on being a cost-effective, one-stop partner for managing escalating R&D costs while protecting client IP.

View full company profile

Therapeutic Areas

Metabolic Disease Oncology Inflammation Immunology Cardiovascular Diseases

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
Undisclosed	Biossil	Phase 2/3	Active